The aim of the present study was to evaluate efficacy, safety, and tolerability of a pediatric colonoscopy bowel preparation regimen composed of polyethylene glycol-3350 (PEG-3350) and a sports drink completed in a few hours.
A prospective, open-label trial of a colonoscopy bowel preparation in children ages 8 to 18 years that included 238 g of PEG-3350 mixed with 1.9 L of Gatorade completed in a few hours. Efficacy was determined using the Boston Bowel Preparation Scale. Basic metabolic profiles and questionnaires were obtained that assessed for safety, adverse effects, tolerability, and patient acceptability.
Forty-six patients completed the study. Patients were predominately boys (56.5%) with a mean age of 14.50 years (SD ±2.9 years). Forty-three (93.5%) were able to complete the regimen. All of the colonoscopies were completed to the cecum and 84% had terminal ileum visualization. Seventy-seven percent were found to be effective preparations. Nausea/vomiting were the most common reported adverse effect (60%) followed by abdominal pain/cramping (44%) and fatigue/weakness (40%). Overall, the regimen was acceptable with 1 exception being the large volume to drink. There were no clinically significant changes in basic metabolic profiles, although there was a statistically significant decrease in the mean potassium (0.16 mEq/L; P = 0.016), blood urea nitrogen (2.68 mg/dL; P < 0.0001), and carbon dioxide (1.89 mmol/L; P < 0.0001).
This study demonstrated that PEG-3350 + Gatorade administered in a few hours is an effective, safe, and moderately tolerable bowel preparation regimen for colonoscopy in children.
*Department of Pediatrics, Walter Reed National Military Medical Center
†Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD
‡Department of Pediatrics, Fort Belvoir Community Hospital, Fort Belvoir, VA.
Address correspondence and reprint requests to Mazen I. Abbas, DO, MPH, Department of Pediatrics, Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889 (e-mail: email@example.com).
Received 9 February, 2012
Accepted 21 June, 2012
www.ClinicalTrials.gov registration number: NCT01518790.
This article has been developed as a Journal CME Activity by NASPGHAN. Visit http://www.naspghan.org/wmspage.cfm?parm1=361 to view instructions, documentation, and the complete necessary steps to receive CME credit for reading this article.
The views expressed in this article are those of the authors and do not reflect the official policy or position of the US Army, the US Air Force, the US Navy, the Department of Defense, or the US government.
The authors report no conflicts of interest.